Clinical Innovation in Obesity: The Next Five Years in Obesity Development

Significant changes have emerged in weight management in the past few years, including proposals to redefine obesity and revise clinical development for treatments. Large real-world studies show incretin therapies can reduce risks for various conditions, with new findings in areas like Alzheimer’s, mental health, and addiction on the horizon.

This presentation will examine the latest global developments in obesity, covering clinical and commercial dynamics, real-world use and policy shaping. Additionally, we will explore how the pipeline will shape this space as next generation agents are brought to market.